Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus CHOP-14 versus CHOP-14 alone in elderly patients with CD20-positive intermediate- or high-risk non-Hodgkin lymphoma
ISRCTN84611849Phase 3Completed
- Sponsor
- HOVON
- Start
- Nov 2001
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-Hodgkin lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma (FL) and 1 more comparing CHOP-14 + pegfilgrastim with Rituximab + CHOP-14 + pegfilgrastim (2 arms). Primary endpoints: Event-free survival and Time to failure for induction failure. Started Nov 2001; status: completed.
02
Drugs
rituximabcyclophosphamide + doxorubicin + vincristine + prednisonepegfilgrastim
03
Conditions
non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN84611849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN84611849.